Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924365 | 0.78 | OPRM1 (0.55) | OPRM1DRD4SLC6A4ALDH1A1OPRK1 | |
| SCHEMBL18588194 | 0.78 | OPRM1 (0.42) | OPRM1 | |
| SCHEMBL16303779 | 0.78 | ALDH1A1 (0.36) | LMNAALDH1A1GAAL3MBTL1 | |
| SCHEMBL19568163 | 0.77 | MAOB (0.40) | OPRM1DRD4MAOBMAOAALDH1A1 | |
| SCHEMBL26026869 | 0.77 | MAOB (0.40) | OPRM1DRD4MAOBMAOAALDH1A1 | |
| SCHEMBL20782184 | 0.77 | SMN1; SMN2 (0.58) | OPRM1DRD4MAOBMAOAALDH1A1 | |
| SCHEMBL20782185 | 0.77 | ALDH1A1 (0.58) | OPRM1DRD4MAOBMAOASLC6A2 | |
| SCHEMBL19567295 | 0.77 | CHRNA7 (0.41) | OPRM1DRD4MAOBMAOALMNA | |
| SCHEMBL26957473 | 0.77 | CHRM2 (0.42) | LMNAALDH1A1CHRM3 | |
| SCHEMBL12367138 | 0.76 | OPRM1 (0.69) | OPRM1DRD4LMNASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017191098-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | OPRM1 2365/4885DRD4 4881/4885MAOB 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.